Moreover, because therapeutic vaccines have shown promising results for PCa treatment, the work of Shen and collaborators [108] is valuable, since combination of the HDAC inhibitor entinostat with the SurVaxM peptide vaccine led to increased beneficial effects in a CRPC model, both by increasing effector cells (CD8-positive cells) and IFN signaling, but also by inhibiting Tregs. Here, HDAC9 is linked to posterior cortical atrophy.